NeuWave Medical’s ablation technology was developed at the University of Wisconson, Ethicon said. The company’s Certus 140 ablation system allows for single or simultaneous multiple probe procedures in patients with soft tissue lesions.
NeuWave won FDA premarket approval for its Ablation Confirmation software last July, saying it would be integrated into its Intelligent Ablation system.
The computer-controlled ablation system also has greater access to data gained during the process and is able to use it to streamline the procedure, CEO Dan Sullivan told MassDevice.com in an interview.
“We continue to work to push the boundaries of access and treatment for patients for whom traditional surgery may not be an option today. The market-leading technology and expertise that NeuWave Medical has developed is minimally invasive and can be combined with other therapies to improve outcomes for patients. Additionally, for healthcare systems, this offering can potentially translate to a lower overall financial burden,” Ethicon group company chair Michael del Prado said in a press release.
Johnson & Johnson said the acquisition falls in line with its “strategy of advancing innovation and investing in areas of unmet medical needs such as surgical oncology.” The company said it expects the transaction to close in the 2nd quarter of 2016.
Financial and other terms of the deal were not announced.